Original researchGlucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction
Introduction
Glucagon-like peptide-1 (GLP-1) analogues are novel antidiabetic agents associated with improvements in glycemic control and with low risk of hypoglycemia when used alone or together with metformin. GLP-1 analogues are also associated with reductions in weight, a high priority for many patients with diabetes [1], [2]. Their most common side effects are nausea and vomiting [3]. Among the two commercially available GLP-1 analogues [1], liraglutide (Victoza, Novo Nordisk) has been demonstrated to have a better effect on glycemic control and fewer side effects than exenatide (Byetta, Lilly/Amylin) in comparative randomized clinical trials [3].
Patients with poor glycemic control, increased body mass index (BMI), and using higher insulin doses are generally difficult to treat optimally due to insulin resistance and weight gain associated with increasing insulin dosages [4], [5]. In spite of a potential for improved metabolic control, there are limited data available on the use of GLP-1 analogues in patients on current insulin therapy, especially with respect to liraglutide [6], [7], [8], [9], although observational data on the use of liraglutide in combination with insulin in 15 patients with type 2 diabetes were recently reported [9]. A recent large clinical trial combined exenatide with insulin glargine [7], but there is a paucity of data on the effect of adding exenatide to patients treated with multiple daily insulin injections.
Despite these limited data, exenatide and liraglutide are used as add-on therapy to patients on different insulin regimens in clinical practice. Hence, there is a need to evaluate the efficacy and safety of these therapies. Therefore, we studied the effect of the addition of GLP-1 analogues on metabolic control and treatment satisfaction in a cohort of patients currently on insulin therapy.
Section snippets
Methods
Records of patients with type 2 diabetes treated at 3 hospital outpatient clinics and 1 primary care clinic in Sweden were retrospectively reviewed by the investigators and diabetic educators at the clinics until 20 December 2010. Since exenatide has been commercially available in Sweden since 2007, records prior to this date were excluded. This study was approved by the ethics committee of Gothenburg University, and all patients provided informed consent.
Variables of interest were glycated
Results
There were 65 patients studied between 2008–2010? Among all patients, 4 discontinued GLP-1 analogue use, 2 for nausea, 1 for fatal myocardial infarction, and 1 for acute sepsis affecting the liver. None discontinued due to hypoglycemia. Patient characteristics at baseline of the 61 patients continuing with GLP-1 analogues are given in Table 1.
Glycemic control was generally poor in the study population, with a mean HbA1c of 8.9% (82.4 mmol/mol). Patients were generally overweight or obese (mean
Discussion
In this observational study of adding GLP-1 analogues to patients on insulin therapy in clinical practice, we demonstrated improvements in glycemic control. At the same time, in this patient group commonly difficult to optimally treat in the presence of obesity and high insulin doses, weight decreased and insulin dosages were reduced. Rates of hypoglycemia were low, and patients reported hypoglycemic problems to be lower with the combination of GLP-1-analogue and insulin than insulin alone in
Conflict of interest
ML has served as consultant or received honoraria from Eli Lilly, Novo Nordisk Scandinavia, Novartis, Pfizer and Sanofi-Aventis, been in the advisory board of Novonordisk Scandinavia and received research grants from Astra Zeneca and Novonordisk Scandinavia. JJ has participated in advisory boards; Eli Lilly, NovoNordisk, Boehringer Ingelheim, Pfizer. Participation in clinical trials; Eli Lilly, NovoNordisk, Sanofi-Aventis, Roche. OT has had lectures for Novonordisk Scandinavia and participated
Acknowledgements
We would like to thank Anette Nilsson at Karlstad Hospital and Helen Bove at Uddevalla Hospital who were central to the data collection process.
References (15)
- et al.
LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
Lancet
(2009) - et al.
Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting
Clin. Ther.
(2009) - et al.
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
BMC Endocr. Disord.
(2010) - et al.
Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes
Curr. Med. Res. Opin.
(2010) Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
Lancet
(1998)- et al.
Insulin-associated weight gain in diabetes – causes, effects and coping strategies
Diabetes Obes. Metab.
(2007) - et al.
Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus
Ann. Pharmacother.
(2010)
Cited by (78)
Factors associated with dissatisfaction with pharmacological treatment in patients with type 2 diabetes mellitus: A cross-sectional study
2023, Journal of Healthcare Quality ResearchDuodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study
2021, Gastrointestinal EndoscopyCitation Excerpt :Recent guidelines promote the use of GLP-1RA as an intermediate step before insulin therapy in T2D patients, yet based on a weighted average of published studies, <10% of patients are able to eliminate insulin therapy after initiation of GLP-1RA monotherapy. In most of these studies, lifestyle counseling was part of the standard study design.11-15 In our study, 69% of patients were able to discontinue insulin therapy, a rate that is hard to explain by the use of GLP-1RA and standard lifestyle counseling only.
The Unmet Medical Needs of Current Injectable Antidiabetic Therapies in China: Patient and Health Care Professional Perspectives
2020, Clinical TherapeuticsCitation Excerpt :Greater treatment satisfaction leads to better adherence and glycemic control, which further reduces the risk of diabetic complications. Previous studies revealed that a convenient injection device could have positive effects on patient satisfaction.20,21 Furthermore, adverse effects9 and high out-of-pocket cost22,23 are the aspects that need to be improved from the patient perspective.
BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus
2017, Pharmacological Research